NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast cancer after one prior chemotherapy regimen, but the manufacturer has been keen to stress that the drug is still available in later settings.
NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer
